Free Technical Research on Abbott Laboratories and Three More Medical Equipment Equities

Stock Research Monitor: VIVE, ABMD, and ALGN

LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on ABT sign up now at www.wallstequities.com/registration. On Tuesday, July 03, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. US markets saw four out of nine sectors finishing the day in red, four in green, and one in neutral territory. Taking into consideration last Tuesday’s market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Viveve Medical Inc. (NASDAQ: VIVE), Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), and Align Technology Inc. (NASDAQ: ALGN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Viveve Medical

On Tuesday, shares in Englewood, Colorado headquartered Viveve Medical Inc. recorded a trading volume of 213,805 shares. The stock ended at $2.80, rising 6.46% from the last trading session. The Company’s shares have gained 9.38% in the last month. The stock is trading above its 50-day moving average by 0.99%. Furthermore, shares of Viveve Medical, which designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions, have a Relative Strength Index (RSI) of 47.18. Get the full research report on VIVE for free by clicking below at:

www.wallstequities.com/registration/?symbol=VIVE

Abbott Laboratories

Abbott Park, Illinois headquartered Abbott Laboratories’ stock finished last Tuesday’s session 0.31% lower at $60.81. A total volume of 2.25 million shares was traded. The Company’s shares have gained 24.84% in the last twelve months. The stock is trading above its 200-day moving average by 4.09%. Furthermore, shares of Abbott Laboratories, which discovers, develops, manufactures, and sells health care products worldwide, have an RSI of 44.15.

On June 27th, 2018, research firm Bernstein initiated an ‘Outperform’ rating on the Company’s stock, with a target price of $73 per share. Get access to our top-rated research, including the free report on ABT at:

www.wallstequities.com/registration/?symbol=ABT

ABIOMED

At the close of trading on Tuesday, shares in Danvers, Massachusetts headquartered ABIOMED Inc. saw a drop of 0.72%, ending the day at $409.53. The stock recorded a trading volume of 291,871 shares. The Company’s shares have advanced 41.94% in the previous three months and 187.81% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 6.79% and 55.74%, respectively. Moreover, shares of ABIOMED, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, have an RSI of 49.39.

On June 22nd, 2018, research firm Piper Jaffray reiterated its ‘Overweight’ rating on the Company’s stock with an increase of the target price from $360 a share to $480 a share. Click here to subscribe for a free membership which welcomes you with our report on ABMD at:

www.wallstequities.com/registration/?symbol=ABMD

Align Technology

San Jose, California headquartered Align Technology Inc.’s shares ended the day 0.47% lower at $338.68 with a total trading volume of 474,844 shares. The stock has gained 36.05% in the previous three months and 127.26% over the last twelve months. The Company’s shares are trading above their 50-day and 200-day moving averages by 8.62% and 31.65%, respectively. Additionally, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intraoral scanners, and computer-aided design and computer-aided manufacturing digital services, have an RSI of 51.32.

On June 25th, 2018, research firm Bank of America/ Merrill resumed its ‘Buy’ rating on the Company’s stock, with a target price of $420 per share. To get free access to your research report on ALGN, sign up at:

www.wallstequities.com/registration/?symbol=ALGN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 504467